✦ LIBER ✦

Matched-pair analysis comparing the outcomes of primary breast and nodal diffuse large B-cell lymphoma in patients treated with rituximab plus chemotherapy

✍ Scribed by Ho-Young Yhim; Jin Seok Kim; Hye Jin Kang; Seok Jin Kim; Won Seog Kim; Chul Won Choi; Hyeon Seok Eom; Jeong-A. Kim; Jae Hoon Lee; Jong Ho Won; Hyeok Shim; Jooryung Huh; Dae-Ho Lee; Cheolwon Suh; Jae-Yong Kwak

Book ID: 112101552
Publisher: John Wiley and Sons
Year: 2011
Tongue: French
Weight: 997 KB
Volume: 131
Category: Article
ISSN: 0020-7136
DOI: 10.1002/ijc.26352

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Serum BAFF predicts prognosis better tha

Serum BAFF predicts prognosis better than APRIL in diffuse large B-cell lymphoma patients treated with rituximab plus CHOP chemotherapy

✍ Seok Jin Kim; Seung Jin Lee; In Young Choi; Yong Park; Chul Won Choi; In Sun Kim 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 139 KB

Lack of prognostic significance of the g

Lack of prognostic significance of the germinal-center phenotype in diffuse large B-cell lymphoma patients treated with CHOP-like chemotherapy with and without rituximab

✍ Ivana Ilić; Zdravko Mitrović; Igor Aurer; Sandra Bašić-Kinda; Ivo Radman; Radmil 📂 Article 📅 2009 🏛 Carden Jennings Publishing 🌐 English ⚖ 268 KB

Bcl-2, Bcl-6, and the International Prog

Bcl-2, Bcl-6, and the International Prognostic Index are prognostic indicators in patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy

✍ Akiko Miyagi Maeshima; Hirokazu Taniguchi; Suguru Fukuhara; Noriyuki Morikawa; W 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 435 KB

Prognostic significance of MYC, BCL2, an

Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab

✍ Nalan Akyurek; Aysegul Uner; Mustafa Benekli; Ibrahim Barista 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 399 KB

The effect of adding rituximab to CHOP-b

The effect of adding rituximab to CHOP-based therapy on clinical outcomes for Japanese patients with diffuse large B-cell lymphoma: a propensity score matching analysis

✍ Hisakazu Nishimori; Keitaro Matsuo; Yoshinobu Maeda; Yuichiro Nawa; Kazutaka Sun 📂 Article 📅 2009 🏛 Carden Jennings Publishing 🌐 English ⚖ 201 KB

Cost utility in the United States of rit

Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B-cell lymphoma

✍ John C. Hornberger; Jennie H. Best 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 114 KB 👁 2 views